Avid Bioservices, Inc. (CDMO)
| Market Cap | 1.58B |
| Revenue (ttm) | 95.87M |
| Net Income (ttm) | 3.32M |
| Shares Out | 60.84M |
| EPS (ttm) | 0.06 |
| PE Ratio | 455.09 |
| Forward PE | 116.28 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $25.94 |
| Previous Close | $25.60 |
| Change ($) | 0.34 |
| Change (%) | 1.33% |
| Day's Open | 25.59 |
| Day's Range | 25.20 - 26.55 |
| Day's Volume | 461,360 |
| 52-Week Range | 6.49 - 27.02 |
Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry E...
-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 --
TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives ...
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on Inves...
Avid Bioservices (CDMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) ...
Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appe...
As of late, it has definitely been a great time to be an investor in Avid Bioservices, Inc. (CDMO).
TUSTIN, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to impr...
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.
Find Strong Stocks to Start Q2 with New Analyst Coverage
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like UFP Industries (UFPI), Interactive Brokers (IBKR), Avid (CDMO), Amtech (ASYS) and GAIA
TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improv...
Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon
TUSTIN, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) w...
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 150.00% and 9.03%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?
TUSTIN, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) w...
Shares of Avid Bioservices (NASDAQ:CDMO) increased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 116.67% over the past year to $0.01, which bea...
-- Third Quarter Revenue Increased 61% to $21.8 Million -- -- S igned $74 Million in New Orders to End the Quarter with a Backlog of $120 Million --
TUSTIN, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improv...
TUSTIN, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improv...
Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites
BURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered ...
TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve...
TUSTIN, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve...
TUSTIN, Ca., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve pa...
TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve...
The company reported great fiscal 2021 Q2 results.
Avid Bioservices' (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript
Shares of Avid Bioservices (NASDAQ:CDMO) moved higher by 8.2% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 133.33% over the past year to $0...
-- Recorded Second Quarter Revenue of $ 21 .1 Million -- -- Signed $28 Million in Business Orders and Ended the Quarter with a Backlog of $67 Million --
TUSTIN, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve...
TUSTIN, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve...
TUSTIN, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual Meeting”)...
TUSTIN, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to impr...
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q1 2021 Results - Earnings Call Transcript
Shares of Avid Bioservices (NASDAQ:CDMO) rose 6.81% after the company reported Q1 results.
-- Recorded First Quarter Revenue of $25.4 Million -- -- S igned Three New Customers and Project Expansion Orders with Current Customers for $20 Million --
TUSTIN, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to impro...
TUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to impro...
TUSTIN, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to impro...
TUSTIN, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to impro...
Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeutics Argon...
Avid Bioservices (CDMO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The company still had significant production problems. But it also picked up a lot of new business in Q4.
Investors need to pay close attention to Avid Bioservices (CDMO) stock based on the movements in the options market lately.
Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q4 2020 Results - Earnings Call Transcript
-- Appointed Nicholas Green as President and Chief Executive Officer -- -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million --
About CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides var... [Read more...]
| Industry Biotechnology | Founded 1981 |
| CEO Nicholas Green | Employees 252 |
| Stock Exchange NASDAQ | Ticker Symbol CDMO |
Analyst Forecasts
According to 3 analysts, the average rating for CDMO stock is "Strong Buy." The 12-month stock price forecast is 28.25, which is an increase of 8.91% from the latest price.